OLEMA PHARMACEUTICALS INC
OLMANASDAQTrading Snapshot
- Day Range
- $8.41 – $8.70
- 52-Week Range
- $6.65 – $36.26
- Volume
- $5.03B
- Avg Volume
- $5.64B
- Shares Outstanding
- 87.3M
- Next Earnings
- Nov 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $68M
- Last Q Revenue
- $17M
- P/E Ratio
- -4.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.96
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +55.5%
Why Investors Own OLMA
- ✓High-growth profile — revenue up +11.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 19% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
OLEMA PHARMACEUTICALS INC
OLMA
StockOtter · stockotter.spaceAbout OLEMA PHARMACEUTICALS INC
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commerciali
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercializ
66,163 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by Connor Clark & Lunn Investment Management Ltd.
Connor Clark and Lunn Investment Management Ltd. bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) during the second quarter, according to its most recent filing with the SEC. The firm bought 66,163 shares
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Pharmaceuticals Inc. (NASDAQ:OLMA) shares are trading lower on Tuesday as the company completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in the first quarter of 2027.